Navigation Links
Aethlon Medical Announces Multi-Target Exosome Assay Validation
Date:4/12/2011

SAN DIEGO, April 12, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.  In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids.  In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer.  ESI is now preparing a market survey that will be provided to researchers to determine market demand and pricing for ELLSA as a research tool.  

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

"We are grateful to those organizations that collaborated in beta-testing the capabilities of ELLSA to detect exosomes, which are increasingly being recognized as particles that deplete immune cells or provide a mechanism to transport disease-enhancing factors below the surveillance of the immune system," stated Aethlon CEO, Jim Joyce. "Additionally, the ESI ELLSA provides the potential for a near-term revenue stream that complements the therapeutic programs we are actively advancing at Aethlon Medical"

About Aethlon Medical

At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical Releases Shareholder Letter
2. Aethlon Medical Receives FDA Approval to Export its Hemopurifier® to India
3. Aethlon Medical Releases Shareholder Letter
4. Aethlon Medical to Host Investor Event on January 20, 2011
5. Aethlon Medical Announces Presentation at U.S. Department of Health and Human Services BARDA Industry Day
6. A Platform Technology to Address Bioterrorism Released by Aethlon Medical, Inc.
7. Aethlon Medical to Present at the Singular Research Fifth Annual Best of the Uncovereds Conference
8. Aethlon Medical Names Rod Kenley President
9. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
10. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
11. Aethlon Medical Reestablishes Biodefense Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Nektar Therapeutics (Nasdaq: NKTR ) today ... 30, 2014. Cash and investments in marketable ... to $309.1 million at March 31, 2014."The second half of ... look forward to significant milestones for a number of our ... Executive Officer of Nektar. "The first of these is the ...
(Date:7/31/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... announced that the Company will release results for the ... before the opening of the U.S. financial markets. The ... at 8:30 a.m. ET to discuss results and highlights ... to be used during the call will be available ...
(Date:7/31/2014)... SARASOTA, Fla. , July 31, 2014 ... announced today that it has initiated the development of ... ; and that it has selected Quotient Clinical, ... United Kingdom (UK) to run its early ... a Clinical Trial Application (CTA) by the end of ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... YORK, March 7, 2012  The Alzheimer,s Drug Discovery ... (AFTD) announced today the recipients of their fifth ... Program.   The goal of the ... therapies for frontotemporal degeneration (FTD).  ...
... OAKS, Calif., March 7, 2012  Amgen Inc. ("Amgen") (NASDAQ: ... offering period of the tender offer (the "Offer") by a ... of common stock of Micromet, Inc. ("Micromet") (NASDAQ: ... offering period expired at 12:00 midnight, New York City time, ...
Cached Medicine Technology:Awards for Drug Discovery Research for Frontotemporal Degeneration Announced 2Awards for Drug Discovery Research for Frontotemporal Degeneration Announced 3Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc. 2Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc. 3Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc. 4
(Date:7/31/2014)... Most mommy blogs are simple family journals, ... to attract all mothers from all walks of life. ... whether its high fashion or child rearing. When Felicia ... the Internet was so segmented. “I found myself visiting ... and then search Google to get information on another. ...
(Date:7/31/2014)... and saliva tests that help accurately predict recurrences of ... The tests screen for DNA fragments of the human ... mouth or other parts of the body. A description ... issue of JAMA Otolaryngology Head & Neck ... in the year after initial therapy to take an ...
(Date:7/31/2014)... 31, 2014 LDM Global ( http://www.ldmglobal.com ... model that is simplified and predictable with fixed fees ... As a leading international provider of legal discovery management ... has become glaringly apparent that both the courts and ... budgets and the complex pricing structure that plagues the ...
(Date:7/31/2014)... HealthDay Reporter THURSDAY, July 31, ... don,t see themselves that way, which makes achieving a ... new study, 27 percent of children and teens underestimated ... 25 percent of parents underestimated their child,s weight and ... "Efforts to prevent childhood obesity should incorporate education ...
(Date:7/31/2014)... ROCHESTER, Minn. Implementation of an algorithm aimed ... the utilization of computed tomography (CT) scans, without ... have found. The study was recently published in ... is the most common cause of acute abdominal ... becomes inflamed and filled with pus. CT scans ...
Breaking Medicine News(10 mins):Health News:Mommylish Launches Its Website 2Health News:Blood and saliva tests help predict return of HPV-linked oral cancers 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:1 in 4 U.S. Kids Underestimate Their Weight, Study Finds 2Health News:1 in 4 U.S. Kids Underestimate Their Weight, Study Finds 3
... , , Magnifies financial and ... impact services and cost to consumers , , ... the proposed Senate health care plan , America,s ... requirements applicable to nonprofit hospitals starting in 2010. According to the ...
... , WASHINGTON, Sept. 16 Today U.S. Sen. ... Health Future Act of 2009" that will be marked-up in ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) , , ... subsidize health plans that cover all elective abortions and moves ...
... Researchers suggest strong disapproval of contraception might be a ... birth rates are higher in states with greater levels ... contraception, a new U.S. study suggests. , In the ... Prevention data on teen birth rates with data from ...
... 20-year follow-up study revealed a dramatic drop in liver cancer ... hepatitis B virus at birth, according to a study published ... Cancer Institute . In July 1984, a universal vaccination ... the hepatitis B virus infection, which can predispose to the ...
... , NEW YORK, Sept. 16 The Nielsen ... CLIO Awards, one of the world,s most recognized international advertising and design ... first-ever CLIO Healthcare Awards to be held on ... contemporary, modern space near Highline Park, befitting an innovative awards show. ...
... , ROCHESTER, Minn., Sept. 16 Here ... HealthSource . You may cite this publication as often as you ... is required. Reprinting is allowed for a fee. Include the ... www.bookstore.mayoclinic.com or call toll-free for subscription information, 800-876-8633, extension ...
Cached Medicine News:Health News:Baucus Bill Imposes Additional Tax Burdens on Nonprofit Hospitals 2Health News:Family Research Council: Senator Baucus Undermines President Obama's Abortion Funding Claim 2Health News:Nielsen Announces First-Ever CLIO Healthcare Awards Mixer on November 13th at Skyline Studios NYC 2Health News:Nielsen Announces First-Ever CLIO Healthcare Awards Mixer on November 13th at Skyline Studios NYC 3Health News:September 2009 Mayo Clinic Women's HealthSource Highlights Ovarian Cancer, Salt and Breaking a Sweat 2Health News:September 2009 Mayo Clinic Women's HealthSource Highlights Ovarian Cancer, Salt and Breaking a Sweat 3Health News:September 2009 Mayo Clinic Women's HealthSource Highlights Ovarian Cancer, Salt and Breaking a Sweat 4Health News:September 2009 Mayo Clinic Women's HealthSource Highlights Ovarian Cancer, Salt and Breaking a Sweat 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: